Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Launched by MELBOURNE HEALTH · Oct 22, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the body processes a medication called Posaconazole, which is commonly used to help prevent serious fungal infections in patients receiving chemotherapy or stem cell transplants. The goal is to understand how well this oral medication works in these patients, as it is a standard part of their care.
To participate in the study, individuals must be adults aged 18 or older who are currently receiving Posaconazole as part of their treatment in a hospital. They will need to be able to provide informed consent, meaning they understand the study and agree to participate. Participants can expect to be involved in monitoring how their bodies respond to the medication, helping researchers gather important information that could improve treatment for future patients. If you're considering joining, it's essential to discuss any questions or concerns with your healthcare team.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.
- • Able to give informed consent.
- Exclusion Criteria:
- • Unable to give informed consent.
About Melbourne Health
Melbourne Health is a leading healthcare provider and research institution based in Melbourne, Australia, dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical research, Melbourne Health collaborates with a network of specialists and researchers to conduct rigorous studies across various therapeutic areas. Committed to ethical standards and patient safety, Melbourne Health emphasizes a patient-centered approach, ensuring that clinical trials are designed to address critical health issues while fostering an environment of scientific inquiry and collaboration. Through its clinical research initiatives, Melbourne Health aims to contribute to the development of effective treatments and enhance the overall quality of care in the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parkville, Victoria, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials